VirnetX Holding Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on August 28, 2024, by VirnetX Holding Corporation (VHC), a Delaware corporation listed on the NYSE. The report addresses a regulatory notice received from the New York Stock Exchange regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing provides specific data points related to the listing deficiency but does not report standard operational financial metrics such as revenue, profit, or cash flow.
- 30-Day Average Market Capitalization: Approximately $23.9 million (as of August 27, 2024).
- Stockholders' Equity: Approximately $48.8 million (as of June 30, 2024).
- NYSE Minimum Market Capitalization Standard: $50 million.
- NYSE Minimum Stockholders' Equity Standard: $50 million.
The filing text does not provide clear values for revenue, operating profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
VirnetX received written notice from the NYSE that it is no longer in compliance with Section 802.01B (Minimum Market Capitalization Standard). The noncompliance is due to the company's average global market capitalization falling below $50 million over a consecutive 30 trading-day period while simultaneously having stockholders' equity below $50 million. The company's stock will continue to trade on the NYSE during the cure period, subject to the acceptance of a compliance plan.
Outlook, Risks, and Management Commentary
Compliance Plan: The company intends to submit a plan to the NYSE within 45 days of receiving the notice to demonstrate how it will regain compliance within 18 months (the "Cure Period").
Risks and Contingencies:
- If the NYSE rejects the plan, the company fails to comply with the plan, or the company does not meet the standard by the end of the Cure Period, the NYSE will initiate suspension and delisting procedures.
- Management states it is considering all available options to regain compliance but provides no assurances that it will be able to maintain its listing.
- The current noncompliance does not affect ongoing business operations or SEC reporting requirements.
Key Facts for Investor Verification
- Verify the specific details of the compliance plan VirnetX intends to submit to the NYSE within the next 45 days.
- Monitor the NYSE's decision on whether to accept the company's plan to regain compliance.
- Track the company's stock price and market capitalization to determine if it can reach the $50 million threshold within the 18-month cure period.
- Review the company's most recent 10-Q or 10-K for detailed revenue, cash flow, and debt information not included in this 8-K.